Back to resultsA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Primary Purpose
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
KIN-2787
KIN-2787 and binimetinib
Sponsored by
About this trial
This is an interventional treatment trial for Solid Tumor, Adult focused on measuring BRAF inhibitor, BRAF, pan-RAF, pan-RAF inhibitor, RAF1, ARAF, BRAF alteration, BRAF Class II, BRAF Class III, V600, tumor growth inhibitor (TGI), melanoma, NSCLC, solid tumor, targeted therapy, BRAF Class I, NRAS, Metastatic, Unresectable, CRC, ATC, Colon, Thyroid, Advanced, Exarafenib, binimetinib
Eligibility Criteria
Inclusion Criteria:
- Provide written informed consent prior to initiation of any study-specific procedures.
- Metastatic or advanced stage solid tumor
- Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.
- Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.
- ECOG performance status 0-1
- Adequate organ function, as measured by laboratory values (criteria listed in protocol).
- Able to swallow, retain, and absorb oral medications.
Exclusion Criteria:
- Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)
- In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
- GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
- Active, uncontrolled bacterial, fungal, or viral infection.
- Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
- Women who are lactating or breastfeeding, or pregnant.
- In Part B Dose Expansion, patients with BRAF Class I mutations are excluded.
- Participants with any other active treated malignancy within 3 years prior to enrollment
Complete inclusion and exclusion criteria are listed in the clinical study protocol.
Sites / Locations
- City of Hope
- Providence
- UCSD Moores Cancer CenterRecruiting
- University of Southern California
- UCLARecruiting
- UC Davis
- Providence Medical Foundation (St. Joseph's)
- Stanford Cancer CenterRecruiting
- Orlando Health Cancer InstituteRecruiting
- Sarah Cannon Research Institute - Lake NonaRecruiting
- Moffitt Cancer CeterRecruiting
- Decatur Memorial HospitalRecruiting
- Center for Cancer and Blood Disorders
- NYU LangoneRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- Cleveland ClinicRecruiting
- Fox Chase Cancer CenterRecruiting
- Thomas JeffersonRecruiting
- Sarah Cannon Research InstituteRecruiting
- Virginia Cancer SpecialistsRecruiting
- Northwest Medical Specialties
- Melanoma Institute AustraliaRecruiting
- Linear Clinical ResearchRecruiting
- Union Hospital of Tongji Medical College of HUST
- Linyi Cancer Hospital
- Beijing University Cancer Hospital
- The Shanghai Pulmonary Hospital
- Institut BergonieRecruiting
- Centre Leon BerardRecruiting
- APHM-CHU La TimoneRecruiting
- CHU Nantes-Hotel DieuRecruiting
- Gustave RoussyRecruiting
- Chungbuk National University Hospital
- Seoul National University Hospital
- Samsung Medical Center
- Netherlands Cancer Institute
- Vall d'Hebron Institute of Oncology (VHIO)Recruiting
- Hospital Quiron DexeusRecruiting
- Hospital Universitario Insular de Gran CanariaRecruiting
- Hospital General Gregorio MarañónRecruiting
- INCLIVA (Hospital Clinico de Valencia)Recruiting
- Taipei Veterans General Hospital
- National Taiwan University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
Dose Escalation Monotherapy (Part A1)
Dose Escalation Combination therapy (Part A2)
Dose Expansion Monotherapy (Part B1)
Dose Escalation Combination therapy (Part B2)
Arm Description
Dose escalation of KIN-2787
Dose escalation of KIN-2787 and binimetinib
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
Outcomes
Primary Outcome Measures
Part A1 Dose escalation monotherapy:
To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation in Part B Dose Expansion.
Part A2 Dose Escalation: KIN-2787 + Binimetinib Combination
To determine the safety and tolerability of oral administration of KIN-2787 + binimetinib including DLTs, and to identify the MTD and/or the appropriate dose for further clinical investigation.
In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.
To assess preliminary evidence of the anti-cancer activity of KIN-2787 and for (B2) KIN-2787 + binimetinib
In Part B (Dose Expansion) - disease control rate (DCR).
In Part B (Dose Expansion) - duration of overall response (DOR).
Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression
In Part B (Dose Expansion) - duration of stable disease.
Secondary Outcome Measures
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to tmax.
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to AUC.
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to Cmax.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to Cmax.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to AUC.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to tmax.
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to AUC.
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to Cmax.
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to tmax.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04913285
Brief Title
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Official Title
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 4, 2021 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kinnate Biopharma
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Detailed Description
This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor.
The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Keywords
BRAF inhibitor, BRAF, pan-RAF, pan-RAF inhibitor, RAF1, ARAF, BRAF alteration, BRAF Class II, BRAF Class III, V600, tumor growth inhibitor (TGI), melanoma, NSCLC, solid tumor, targeted therapy, BRAF Class I, NRAS, Metastatic, Unresectable, CRC, ATC, Colon, Thyroid, Advanced, Exarafenib, binimetinib
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
400 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Dose Escalation Monotherapy (Part A1)
Arm Type
Experimental
Arm Description
Dose escalation of KIN-2787
Arm Title
Dose Escalation Combination therapy (Part A2)
Arm Type
Experimental
Arm Description
Dose escalation of KIN-2787 and binimetinib
Arm Title
Dose Expansion Monotherapy (Part B1)
Arm Type
Experimental
Arm Description
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
Arm Title
Dose Escalation Combination therapy (Part B2)
Arm Type
Experimental
Arm Description
Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
Intervention Type
Drug
Intervention Name(s)
KIN-2787
Other Intervention Name(s)
exarafenib
Intervention Description
KIN-2787 will be administered orally twice daily in 28-day cycles
Intervention Type
Drug
Intervention Name(s)
KIN-2787 and binimetinib
Other Intervention Name(s)
exarafenib and binimetinib
Intervention Description
KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
Primary Outcome Measure Information:
Title
Part A1 Dose escalation monotherapy:
Description
To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation in Part B Dose Expansion.
Time Frame
Initiation of study drug through 28 days after last dose (up to approximately 18 months)
Title
Part A2 Dose Escalation: KIN-2787 + Binimetinib Combination
Description
To determine the safety and tolerability of oral administration of KIN-2787 + binimetinib including DLTs, and to identify the MTD and/or the appropriate dose for further clinical investigation.
Time Frame
Initiation of study drug through 28 days after last dose (up to approximately 18 months)
Title
In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.
Description
To assess preliminary evidence of the anti-cancer activity of KIN-2787 and for (B2) KIN-2787 + binimetinib
Time Frame
Initiation of study drug until disease progression (up to approximately 36 months)
Title
In Part B (Dose Expansion) - disease control rate (DCR).
Time Frame
Initiation of study drug until disease progression (up to approximately 36 months)
Title
In Part B (Dose Expansion) - duration of overall response (DOR).
Description
Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression
Time Frame
Initiation of study drug until disease progression (up to approximately 36 months)
Title
In Part B (Dose Expansion) - duration of stable disease.
Time Frame
Initiation of study drug until disease progression (up to approximately 36 months)
Secondary Outcome Measure Information:
Title
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to tmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to AUC.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to Cmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to Cmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to AUC.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to tmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to AUC.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to Cmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
Title
Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to tmax.
Time Frame
Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provide written informed consent prior to initiation of any study-specific procedures.
Metastatic or advanced stage solid tumor
Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.
Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.
ECOG performance status 0-1
Adequate organ function, as measured by laboratory values (criteria listed in protocol).
Able to swallow, retain, and absorb oral medications.
Exclusion Criteria:
Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)
In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
Active, uncontrolled bacterial, fungal, or viral infection.
Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
Women who are lactating or breastfeeding, or pregnant.
Participants with any other active treated malignancy within 3 years prior to enrollment
Complete inclusion and exclusion criteria are listed in the clinical study protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kinnate Clinical Operations
Phone
858.252.2723
Email
clinicaltrials@kinnate.com
Facility Information:
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Completed
Facility Name
Providence
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Individual Site Status
Completed
Facility Name
UCSD Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julia Appelt, CCRC
Phone
858-822-0201
Email
jappelt@health.ucsd.edu
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Completed
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Crocker
Email
JCrocker@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Bartosz Chmielowski, MD
Facility Name
UC Davis
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Completed
Facility Name
Providence Medical Foundation (St. Joseph's)
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Individual Site Status
Completed
Facility Name
Stanford Cancer Center
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Debjani Ghoshal
Email
dghoshal@stanford.edu
First Name & Middle Initial & Last Name & Degree
Chris Chen, MD
Email
ctjchen@stanford.edu
First Name & Middle Initial & Last Name & Degree
Chris Chen, MD
Facility Name
Orlando Health Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sajeve Thomas, MD
Email
Sajeve.Thomas@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Sajeve Thomas, MD
Facility Name
Sarah Cannon Research Institute - Lake Nona
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
asksarah@sarahcannon.com
Facility Name
Moffitt Cancer Ceter
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cody Likens
Email
cody.likens@moffitt.org
First Name & Middle Initial & Last Name & Degree
Hao Xie, MD, PhD
Facility Name
Decatur Memorial Hospital
City
Decatur
State/Province
Illinois
ZIP/Postal Code
62526
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Wade
Phone
217-876-6600
Email
jlwade3@sbcglobal.net
First Name & Middle Initial & Last Name & Degree
James Wade, MD
Facility Name
Center for Cancer and Blood Disorders
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Individual Site Status
Completed
Facility Name
NYU Langone
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
CT.gov@nyulangone.org
First Name & Middle Initial & Last Name & Degree
Janice Mehnert, MD
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Offin
Email
offinm@mskcc.org
First Name & Middle Initial & Last Name & Degree
Michael Offin, MD
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
TaussigResearch@ccf.org
Phone
216-444-7923
First Name & Middle Initial & Last Name & Degree
Dale Shepard, MD, PhD
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Olszanski, MD
Email
Anthony.Olszanski@fccc.edu
First Name & Middle Initial & Last Name & Degree
Anthony Olszanski, MD
Facility Name
Thomas Jefferson
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sheri McDougall
Phone
215-503-1011
Email
Sheri.McDougall@jefferson.edu
Phone
215-503-1012
First Name & Middle Initial & Last Name & Degree
Marcia Simpson Brose, MD
Facility Name
Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
844-482-4812
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carrie Friedman, RN, BSN, OCN
Phone
703-636-1473
Email
vcsclinicaltrials@usoncology.com
Facility Name
Northwest Medical Specialties
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Completed
Facility Name
Melanoma Institute Australia
City
Wollstonecraft
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Individual Site Status
Recruiting
Facility Name
Linear Clinical Research
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Millward, Professor
Phone
(08) 6382 5100
Email
cancertrialsstartup@linear.org.au
Facility Name
Union Hospital of Tongji Medical College of HUST
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430023
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Linyi Cancer Hospital
City
Linyi
State/Province
Shandong
ZIP/Postal Code
276001
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Beijing University Cancer Hospital
City
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Active, not recruiting
Facility Name
The Shanghai Pulmonary Hospital
City
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Active, not recruiting
Facility Name
Institut Bergonie
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonie Italiano
Phone
+33 5 47 30 60 88
Email
a.italiano@bordeaux.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Antonie Italiano, MD
Facility Name
Centre Leon Berard
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Cassier
Phone
+33 4 26 55 68 33
Email
philippe.cassier@lyon.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Philippe Cassier, MD
Facility Name
APHM-CHU La Timone
City
Marseille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Gaudy
Phone
+33 (0) 4 91 38 75 94
Email
mailto:caroline.gaudy@ap-hm.fr
Facility Name
CHU Nantes-Hotel Dieu
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Bordenave
Phone
+33 2 40 16 59 30
Email
stephanie.bordenave@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
Stephanie Bordenave, MD
Facility Name
Gustave Roussy
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Planchard, MD
Phone
+ 33 (0)1 42 11 45 64
Email
David.PLANCHARD@gustaveroussy.fr
First Name & Middle Initial & Last Name & Degree
David Planchard, MD
Facility Name
Chungbuk National University Hospital
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Netherlands Cancer Institute
City
Amsterdam
Country
Netherlands
Individual Site Status
Completed
Facility Name
Vall d'Hebron Institute of Oncology (VHIO)
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Muñoz
Phone
+ 34 34 93 274 60 00
Email
emunoz@vhio.net
First Name & Middle Initial & Last Name & Degree
Eva Muñoz, MD
Facility Name
Hospital Quiron Dexeus
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
María María González Cao, MD
Phone
+34 93 546 01 35
Email
mgonzalezcao@oncorosell.com
First Name & Middle Initial & Last Name & Degree
María María González Cao, MD
Facility Name
Hospital Universitario Insular de Gran Canaria
City
Las Palmas De Gran Canaria
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Delvys Rodríguez
Phone
+34 928 44 17 38
Email
drodabr@gobiernodecanarias.org
First Name & Middle Initial & Last Name & Degree
Delvys Rodríguez, MD
Facility Name
Hospital General Gregorio Marañón
City
Madrid
ZIP/Postal Code
29009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Calles Blanco, MD
Phone
+ 34 914 26 95 16
Email
antonio.calles@live.com
Phone
+ 34 915 86 81 15
First Name & Middle Initial & Last Name & Degree
Antonio Calles Blanco, MD
Facility Name
INCLIVA (Hospital Clinico de Valencia)
City
Valencia
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valentina Gambardella, MD
Phone
+34 961 97 35 31/+34 961 97 4
Email
valen.gambardella@gmail.com
First Name & Middle Initial & Last Name & Degree
Valentina Gambardella, MD
Facility Name
Taipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan
Individual Site Status
Completed
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Active, not recruiting
12. IPD Sharing Statement
Learn more about this trial
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
We'll reach out to this number within 24 hrs